Previous 10 | Next 10 |
Curis Highlights Publication in ACS Medicinal Chemistry Letters Showcasing Targeted Potency and Ideal Pharmacologic Properties of CA-4948 for Treatment of Hematologic Malignancies PR Newswire LEXINGTON, Mass., Oct. 21, 2020 LEXINGTON, Mass. , Oct. 21, 2020 /P...
Curis Announces Abstract for CI-8993 Accepted for Presentation at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting PR Newswire LEXINGTON, Mass., Oct. 14, 2020 LEXINGTON, Mass. , Oct. 14, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ...
Gainers: MyoKardia (MYOK) +58%, Eidos Therapeutics (EIDX) +41%, Enlivex Therapeutics (ENLV) +25%, Humanigen (HGEN) +28%, Corvus Pharmaceuticals (CRVS) +26%.Losers: Xtant Medical Holdings (XTNT) -15%, Curis (CRIS) -7%, Immunome (...
LEXINGTON, Mass. , Sept. 10, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer , President and Chief Executive Officer of Curis, will provide ...
AnPac Bio-Medical Science (NASDAQ: ANPC ) +112% . on validating approved COVID-19 antibody test. More news on: AnPac Bio-Medical Science Co., Ltd., Huttig Building Products, Inc., Plus Therapeutics, Inc., , Read more ...
Curis, Inc. (CRIS) Q2 2020 Earnings Conference Call August 04, 2020 04:30 PM ET Company Participants Bill Steinkrauss - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Bob Martell - Head of R&D Conference Call Participants Alethia Young - ...
Curis (NASDAQ: CRIS ) : Q2 GAAP EPS of -$0.17 beats by $0.03 . Revenue of $2.36M (+12.9% Y/Y) misses by $0.34M . Shares +1.5% . Press Release More news on: Curis, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, ,
LEXINGTON, Mass. , Aug. 4, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2020 . "Our...
LEXINGTON, Mass. , July 28, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2020 financial results on Tuesday,...
LEXINGTON, Mass. , July 7, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1 trial evaluating CA-4948, a nove...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...